Axel Bolte - 15 May 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Director
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte
Issuer symbol
INZY
Transactions as of
15 May 2025
Net transactions value
+$154,085
Form type
4
Filing time
20 May 2025, 16:00:06 UTC
Previous filing
20 Jun 2024
Next filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bolte Axel Director C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON /s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte 20 May 2025 0001579247

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Options Exercise $149,767 +152,823 +57% $0.9800 419,519 15 May 2025 Direct
transaction INZY Common Stock Options Exercise $4,319 +4,407 +1.1% $0.9800 423,926 15 May 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock Option (right to buy) Options Exercise $0 -152,823 -100% $0.000000 0 15 May 2025 Common Stock 152,823 $0.9800 Direct F1
transaction INZY Stock Option (right to buy) Options Exercise $0 -4,407 -100% $0.000000 0 15 May 2025 Common Stock 4,407 $0.9800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options are fully vested.